Gregory Macaluso, MD
Cardiovascular Disease · Maywood, ILNPI 1831355585
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,754 of the $164,600 with a category attached, or 74.6%. It is spread thinly across 38 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2019 at $38,959 and has fallen 91.4% since, to $3,365 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 867 payments — averaging $189.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$39K
- AstraZeneca$33K
- Novartis$33K
- Lexicon Pharmaceuticals, Inc.$26K
- Medtronic$13K
- United Therapeutics Corporation$9K
- plus $12K from 32 others
Across 10 payments — averaging $31,241 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$298K
- Abbott$14K
What the payments were for
- Consulting fees$14,4629%
- Speaking & faculty fees$122,75475%
- Travel & lodging$4,5943%
- Food & beverage$22,57414%
- Education$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$31,766
- FARXIGA$28,124
- Inpefa$25,751
- HeartWare HVAD$8,963
- CARDIOMEMS$8,209
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$6,864
- CardioMEMS HF System$5,750
- HeartMate$4,862
- LOKELMA$3,801
- ORENITRAM$3,495
- REMODULIN$3,495
- TYVASO$3,495
- CentriMag$2,625
- Gallant CRT-D$2,625
- Confirm Rx$1,969
- FUROSCIX$1,050
- HeartMate Touch$709
- Assure WCD$708
- VYNDAQEL$700
- ENSITE$595
How this compares
$164,600 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 384 | $546,985 |
| VyndamaxTafamidis | 21 | $513,788 |
| VyndaqelTafamidis Meglumine | 23 | $507,461 |
| AdempasRiociguat | 30 | $414,803 |
| CamzyosMavacamten | 27 | $225,754 |
| JardianceEmpagliflozin | 169 | $189,146 |
| FarxigaDapagliflozin Propanediol | 182 | $186,097 |
| EliquisApixaban | 123 | $146,269 |
| XareltoRivaroxaban | 19 | $21,756 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $20,033 |
| Repatha SureclickEvolocumab | 17 | $11,793 |
| Metoprolol Succinate | 313 | $4,076 |
| Midodrine Hcl | 18 | $3,441 |
| Spironolactone | 413 | $3,360 |
| Torsemide | 123 | $3,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $1,149 | $1,167,517167 claims |
| NovartisEntresto | $32,831 | $546,985384 claims |
| BayerAdempas | $111 | $414,80330 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $936 | $225,75427 claims |
| AstraZenecaFarxiga, Lokelma | $32,920 | $206,130209 claims |
| Boehringer IngelheimJardiance | $1,161 | $189,146169 claims |
| Johnson & JohnsonXarelto | $731 | $21,75619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Maywood
- Niraj VarmaMaywood$522K
- Mark RabbatMaywood$363K
- Smit VasaiwalaMaywood$264K
- Clifford KavinskyMaywood$260K
- Dana JohnsonMaywood$104K
- Erin CoglianeseMaywood$36K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.